Vancouver, British Columbia, November 1, 2022 /PRNewswire/ — Motion sickness is likely to increase in the near future, as outdoor travel is projected to increase, and self-driving vehicles are increasingly likely to report increased incidences of nausea and vomiting. is continuously increasing. concern of millions of people around the world. EmeTerm is an FDA-cleared device developed as a safe alternative treatment for motion sickness without the need for drug introduction, avoiding unwanted side effects and unpredictable drug interactions.
Today, cars are not just a means of transportation, but a “good partner” in our lives. With over 12 years of experience and intellectual property in the field of targeted neuromodulation, WAT Medical develops automotive grade neuromodulation products for Geely Group.
This project uses medicine, engineering, materials science, and computer technology across multiple disciplines to provide solutions to prevent fatigue driving and motion sickness induced by specific wavelengths (470nm) of blue light and PC6 electrical stimulation. and enhance your travel experience depending on the car. industry standard.
WAT Medical develops innovative home medical devices through targeted neuromodulation technology and holds over 70 patents worldwide. North AmericaWAT Medical’s motion sickness wristbands and migraine treatment devices are sold in over 30 countries and have insurance reimbursement in the US and USA. Denmark. co-founder peter gee Received the 2021 Innovation Award from University of California, Berkeley.
Geely Holding Group is committed to becoming a globally competitive and influential smart electric mobility and energy services technology company. Ranked among the top 10 global automotive brands by portfolio value, Geely aims to create travel experiences that exceed users’ expectations with its high-quality, technologically advanced products.
To download multimedia, please view the original content. .html
Source WAT Medical Enterprise Ltd.